CG Oncology, Inc. (CGON) Price & Analysis

Compare

213 Followers

CGON Stock Chart & Stats

Day’s Range― - ―

52-Week Range$14.80 - $42.27

Previous Close$30.46

Volume740.02K

Average Volume (3M)1.05M

Market Cap

$2.90B

Enterprise Value$1.32B

Total Cash (Recent Filing)$661.05M

Total Debt (Recent Filing)$994.00K

Price to Earnings (P/E)―

Beta1.86

Next Earnings

Nov 18, 2025

EPS Estimate

-0.56

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.54

Shares Outstanding76,247,580

10 Day Avg. Volume750,343

30 Day Avg. Volume1,054,284

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.46

Enterprise Value/Revenue2.40K

Enterprise Value/Gross Profit3.35K

Enterprise Value/Ebitda-8.41

Forecast

1Y Price Target

$68.08

Price Target Upside67.23% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering13

Bulls Say, Bears Say

Bulls Say

Competitive PositioningCreto's best-in-disease durability and safety, in addition to its ease of administration/logistics, position it competitively.

Market OpportunityThe nascent NMIBC drug market has lots of patients, industry pricing power, and long treatment durations, which makes the CGON story rise to the top of quality oncology ideas, given the best-in-class efficacy, durability, and safety of cretostimogene.

Regulatory PathwayThe approval of Inlexzo strengthens confidence in creto's regulatory pathway ahead as well as peak sales potential.

Bears Say

Pricing And AdoptionThe nearly $1M cost per course could limit adoption in broader NMIBC subsets, such as intermediate-grade or BCG-naïve patients, where cheaper alternatives are likely to remain the first-line standard.

Regulatory ChallengesPotential headwinds include a potential longer time to BLA completion and CRL concerns in the space.

CG Oncology, Inc. News

CG Oncology initiated with a Buy at Guggenheim

Guggenheim analyst Brad Canino initiated coverage of CG Oncology (CGON) with a Buy rating and $90 price target...

3d ago

CGON

CG Oncology price target raised to $47 from $41 at JPMorgan

JPMorgan raised the firm’s price target on CG Oncology (CGON) to $47 from $41 and keeps an Overweight...

14d ago

CGON

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

21d ago

CGON

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

22d ago

CGON

SPRB

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

23d ago

CGON

SPRB

CG Oncology price target raised to $79 from $56 at Morgan Stanley

Morgan Stanley raised the firm’s price target on CG Oncology (CGON) to $79 from $56 and keeps an...

23d ago

CGON

Citizens JMP healthcare analysts hold an analyst/industry conference call

Healthcare Analysts discuss the emerging treatment options for high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) (relevant companies ENGN CGON...

24d ago

JNJ

CGON

Buy Rating for CG Oncology: Creto’s Market Potential and Strategic Pricing Flexibility

H.C. Wainwright analyst Andres Y. Maldonado has maintained their bullish stance on CGON stock, giving a Buy rating...

25d ago

CGON

Citizens JMP healthcare analysts hold an analyst/industry conference call

Healthcare Analysts discuss emerging treatment options for High-Rick Non-Muscle Invasive Bladder Cancer (NMIBC) (relevant companies ENGN CGON JNJ...

1M ago

JNJ

CGON

CG Oncology Highlights Drug Potential at Healthcare Conference

An update from CG Oncology, Inc. ( ($CGON) ) is now available. CG Oncology, Inc. presented an updated...

1M ago

CGON

CG Oncology initiated with a Buy at JonesResearch

JonesResearch initiated coverage of CG Oncology (CGON) with a Buy rating and $50 price target The late-stage company...

1M ago

CGON

Buy Rating for CG Oncology: Promising NMIBC Treatment and Strong Financial Position

CG Oncology, Inc. (CGON) has received a new Buy rating, initiated by JonesTrading analyst, Soumit Roy. Soumit Roy’s...

1M ago

CGON

Buy Rating for CG Oncology, Inc.: Promising Data on Creto’s Efficacy and Safety in NMIBC Treatment

Bank of America Securities analyst Alec Stranahan maintained a Buy rating on CG Oncology, Inc. on September 5...

1M ago

CGON

CG Oncology’s Promising Clinical Results and Strategic Positioning Drive Buy Rating

Morgan Stanley analyst Sean Laaman maintained a Buy rating on CG Oncology, Inc. on September 5 and set...

1M ago

CGON

CGON FAQ

What was CG Oncology, Inc.’s price range in the past 12 months?

CG Oncology, Inc. lowest stock price was $14.80 and its highest was $42.27 in the past 12 months.

What is CG Oncology, Inc.’s market cap?

CG Oncology, Inc.’s market cap is $2.90B.

When is CG Oncology, Inc.’s upcoming earnings report date?

CG Oncology, Inc.’s upcoming earnings report date is Nov 18, 2025 which is in 39 days.

How were CG Oncology, Inc.’s earnings last quarter?

CG Oncology, Inc. released its earnings results on Aug 08, 2025. The company reported -$0.54 earnings per share for the quarter, missing the consensus estimate of -$0.466 by -$0.074.

Is CG Oncology, Inc. overvalued?

According to Wall Street analysts CG Oncology, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does CG Oncology, Inc. pay dividends?

CG Oncology, Inc. does not currently pay dividends.

What is CG Oncology, Inc.’s EPS estimate?

CG Oncology, Inc.’s EPS estimate is -0.56.

How many shares outstanding does CG Oncology, Inc. have?

CG Oncology, Inc. has 76,247,580 shares outstanding.

What happened to CG Oncology, Inc.’s price movement after its last earnings report?

CG Oncology, Inc. reported an EPS of -$0.54 in its last earnings report, missing expectations of -$0.466. Following the earnings report the stock price went up 2.053%.

Which hedge fund is a major shareholder of CG Oncology, Inc.?

Currently, no hedge funds are holding shares in CGON

CG Oncology, Inc. Stock Smart Score

Neutral

Fundamentals

Return on Equity

-20.95%

Trailing 12-Months

Asset Growth

24.30%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

CG Oncology, Inc.

CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

CG Oncology, Inc. (CGON) Earnings & Revenues

Historic Earnings Reports

CGON Stock 12 Month Forecast

Average Price Target

$68.08

▲(67.23% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"21":"$21","56":"$56","91":"$91","38.5":"$38.5","73.5":"$73.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":90,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$90.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":68.08,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$68.08</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":47,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$47.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[21,38.5,56,73.5,91],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39.46,43.347692307692306,47.23538461538462,51.12307692307692,55.01076923076923,58.89846153846154,62.786153846153844,66.67384615384616,70.56153846153846,74.44923076923077,78.33692307692309,82.22461538461539,86.1123076923077,{"y":90,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39.46,41.66153846153846,43.863076923076925,46.06461538461539,48.26615384615385,50.46769230769231,52.669230769230765,54.87076923076923,57.07230769230769,59.27384615384615,61.47538461538461,63.676923076923075,65.87846153846154,{"y":68.08,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39.46,40.04,40.62,41.2,41.78,42.36,42.94,43.52,44.1,44.68,45.26,45.84,46.42,{"y":47,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":36.9,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.91,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.77,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.68,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.07,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.86,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.05,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.74,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.59,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.35,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.31,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.46,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.46,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >